CashuVanda Pharmaceuticals Secures FDA Approval for Bysanti in Bipolar I and Schizophrenia Treatment22 minutes ago
CashuVanda Pharmaceuticals Receives FDA Approval for Bysanti, Enhancing Bipolar Disorder and Schizophrenia Treatments2 days ago
CashuVanda Pharmaceuticals Faces FDA Rejection of HETLIOZ® Amid Ongoing Regulatory Disputeabout 1 month ago
benzinga.comImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Mondayabout 11 hours ago
benzinga.comVanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatmentabout 12 hours ago
benzinga.comImmuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Sessionabout 2 months ago
prnewswire.comVanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorderabout 2 months ago
benzinga.comS&P 500 Falls For Fourth Session But Records Gains In 2025: Investor Sentiment Declines, Fear & Greed Index Remains In 'Neutral Zoneabout 2 months ago